What the Optima Genomic-Test Breakthrough Could Mean for Breast Cancer Treatment Decisions

A breast cancer diagnosis can bring a long list of difficult decisions. Surgery, radiation, hormone therapy, chemotherapy, and additional testing may all become part of the conversation. For many people, one question feels especially urgent: Will chemotherapy help me, or could I safely avoid it?

In moments like that, progress matters most when it becomes understandable. The real promise of a research advance isn’t only what scientists discover. It’s what patients are able to do with that information: ask better questions, weigh options with confidence, and move forward with clarity.

New findings from the international Optima trial may help doctors answer that chemotherapy question more precisely for a specific group of patients with hormone-positive breast cancer. The findings were reported by The Guardian on May 29, 2026, and presented at the 2026 American Society of Clinical Oncology annual meeting in Chicago (The Guardian, 2026).

The results are encouraging. They also need to be understood carefully. This is what progress can look like: evidence moving closer to the patient, while patients remain at the center of every treatment decision.

What did the Optima trial study?

The Optima international trial was led by University College London. It included 4,429 patients aged 40 and older with hormone-positive breast cancer. Participants were in the United Kingdom, Norway, Sweden, Australia, New Zealand, and Thailand (The Guardian, 2026).

Hormone-positive breast cancer accounts for up to 80% of breast cancer cases globally. These cancers use hormones, such as estrogen or progesterone, to grow. Hormone therapy can help block or reduce that hormonal stimulation.

The trial examined whether a genomic test could help identify which patients were less likely to benefit from chemotherapy. The test used in the study was Prosigna, made by Veracyte.

Prosigna analyzes the activity of 50 genes in tumor tissue. It identifies the tumor’s molecular subtype and provides a score estimating the risk of recurrence over 10 years (The Guardian, 2026).

This type of information can add another layer to treatment planning. Instead of relying only on traditional tumor information, an oncology team may also consider how the genes in the tumor are behaving.

What were the key findings?

Among patients with low Prosigna scores, five-year recurrence-free survival was:

• 95% for those who received chemotherapy plus hormone therapy
• 94% for those who received hormone therapy alone

In other words, the reported outcomes were very similar for the low-score group, whether chemotherapy was included or not (The Guardian, 2026).

The findings suggest that some patients with low genomic-risk scores may be able to avoid chemotherapy without compromising the reported five-year recurrence-free outcomes. That possibility could spare them from toxic side effects that may include hair loss, nausea, fatigue, infertility, cognitive impairment, and early menopause (The Guardian, 2026).

As Professor Rob Stein, the trial’s chief investigator, said, “Our findings show that many patients can safely avoid chemotherapy without compromising their outcomes” (as cited in The Guardian, 2026).

That statement reflects the potential importance of the research. It doesn’t mean that chemotherapy is unnecessary for everyone with hormone-positive breast cancer. It also doesn’t mean that every patient with a low score will receive the same recommendation.

Why genomic information may matter

Breast cancer treatment decisions can be complicated because two tumors that look similar under a microscope may behave differently. A genomic test may help provide additional information about the biology of an individual tumor.

For someone considering treatment, the result may help clarify:

• How active certain genes are in the tumor
• Which molecular subtype the tumor has
• The estimated risk of recurrence over 10 years
• Whether chemotherapy is likely to add meaningful benefit to hormone therapy

A low score could support a conversation about hormone therapy without chemotherapy. A result that doesn’t fall into the low-score category could lead to a different discussion.

The broader goal is more personalized treatment. That means matching the intensity of treatment to the characteristics of the disease whenever the evidence supports doing so. It may also help health systems use resources more efficiently by reducing treatments that are unlikely to provide additional benefit for some patients (The Guardian, 2026).

What this may mean for people facing treatment decisions

If you or someone you love is making treatment decisions, the Optima findings may offer another topic to raise with an oncology team.

You could ask:

1. Is genomic testing appropriate for my type of breast cancer?
   The Optima trial studied patients aged 40 and older with hormone-positive breast cancer. Your oncology team can explain whether your diagnosis fits the population studied.

2. What does the test measure?
   Ask whether the test analyzes tumor tissue, what the gene-activity results mean, and how the molecular subtype is identified.

3. How would the result affect my treatment recommendation?
   Ask what a low, intermediate, or high result would mean in your specific situation. You can also ask how the result would be considered alongside other medical information.

4. What are the possible benefits and limitations?
   A genomic score may provide useful information, but it may not answer every treatment question. Ask what the test can and can’t predict.

5. Is the test available, and what would it cost?
   Ask whether the test is offered through your care system, whether insurance may cover it, and whether financial assistance or other options exist. Availability and cost may differ by location and circumstance.

6. What would follow-up care look like?
   Ask about hormone therapy, monitoring, follow-up appointments, and what symptoms or concerns should be reported.

It may help to bring a trusted support person, take notes, or ask whether the oncology team can provide written information. Complex medical conversations can be difficult to absorb in one visit.

Access and equity deserve attention

A treatment advance can only help people who can access it and understand what it means.

Genomic testing may not be equally available to every patient. Cost, insurance questions, location, laboratory access, clinician familiarity, interpretation, and follow-up care can all affect whether someone benefits from testing.

These concerns may be especially important for underserved communities. People may face transportation barriers, limited appointment time, language differences, financial pressure, or difficulty finding culturally responsive information.

Clear education and patient navigation can make complex information easier to discuss. Culturally responsive support may also help patients and families ask questions, understand their options, and participate more fully in shared decision-making. This kind of support can complement medical care, but it doesn’t replace individualized guidance from qualified healthcare professionals.

At I Will Survive, Inc., we believe progress should travel beyond the conference stage and into everyday conversations in clinics, homes, churches, and community spaces. That’s one reason donor support matters. Charitable gifts can help expand access to culturally responsive breast-health education, navigation, and community support so more women can ask informed questions and connect with care. When appropriate, some donors may choose to give at levels such as a monthly contribution or a one-time annual gift, but it’s important to frame that support responsibly: gifts help sustain program priorities and eligible needs rather than guaranteeing a specific test, appointment, treatment, or outcome for any individual.

For general information about finding breast cancer support resources, readers can explore I Will Survive, Inc.’s breast cancer help resource page. The information a person receives should always be discussed with their own care team.

This is not prevention: and it isn’t a universal standard of care

It’s important to distinguish risk reduction, prevention, and treatment.

The Optima findings concern treatment decisions after a person has been diagnosed with hormone-positive breast cancer. The Prosigna test does not prevent breast cancer. It also isn’t a substitute for screening, diagnosis, or inherited-risk evaluation when those services are appropriate.

The Optima results represent a research advance. They were presented at a major medical meeting, but they should not be treated as a universal standard of care. The results apply to the population studied. They should not be generalized to people who fall outside that population without careful medical review.

Patients should not start, stop, or change chemotherapy, hormone therapy, or any other treatment based on this article.

A careful next step

If the Optima findings raise questions, perhaps write them down before your next appointment. Ask whether genomic testing is appropriate, what the result could mean, and how your oncology team would combine it with the rest of your medical information.

Treatment decisions can carry physical, financial, and emotional consequences. You deserve clear explanations and enough time to understand your options. Bringing a support person, requesting an interpreter, or asking for written materials may help you take part in the conversation.

If this article reflects the kind of future you want to help build, perhaps consider supporting I Will Survive, Inc. Your donation helps strengthen breast-health education, navigation, and community support for women and families who need clear information and compassionate connection. Every contribution supports program priorities and eligible needs so more people can ask informed questions and find a pathway to care.

Concise takeaway

The Optima trial found that, among studied patients aged 40 and older with hormone-positive breast cancer and low genomic-test scores, five-year recurrence-free survival was similar with hormone therapy alone and with chemotherapy plus hormone therapy: 94% versus 95% (The Guardian, 2026).

That could help some patients avoid chemotherapy and its potential side effects. It’s a meaningful research advance and a hopeful sign of what patient-centered progress can look like. However, the findings apply only to the studied population and aren’t yet a universal standard of care. The best next step is to discuss genomic testing and treatment options with your oncology team.

Three alternative headline options

1. Optima Trial Findings: How Genomic Testing May Personalize Breast Cancer Treatment
2. Could a Genomic Test Help Some Breast Cancer Patients Avoid Chemotherapy?
3. What Patients Should Know About the Optima Trial and Prosigna Genomic Testing

Meta description

Learn what the Optima trial found about Prosigna genomic testing, chemotherapy decisions, access, equity, and questions to ask your oncology team.

Medical disclaimer

This article is for educational purposes only. It doesn’t replace screening, diagnosis, treatment, genetic counseling, or individualized medical advice. Consult your oncology team and other qualified healthcare professionals before making any healthcare decision.

References

The Guardian. (2026, May 29). Groundbreaking genomic test could spare millions of breast cancer patients chemotherapy. https://www.theguardian.com/society/2026/may/29/groundbreaking-genomic-test-spare-breast-cancer-patients-chemotherapy-hormone-therapy